Y Vashum

Y Vashum


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2020 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
YVY Vashum
Y Vashum
KKKhashim Khashim
Khashim Khashim
Background: Breast cancer appears in a strong inclination to metastasize in bone tissue. Several strategies are discussed in combating bone metastasis in breast cancer. However, therapy is only palliative and does not provide any improvement in survival to the majority of patients with advanced cancer. Obese and overweight women with breast cancer are three times more likely to develop metastatic disease compared to normal-weight women with the same treatment regimen. Overweight greatly intensify adipocytes formation in the bone marrow affecting bone metabolism by decreasing osteoblast differentiation and bone formation. Cathepsin K (CTSK), a cysteine protease, effectively degrades several components of the extracellular matrix and has the ability to differentiate adipocytes from bone marrow lineage. Therefore, the purpose of this review is to emphasize the underlying mechanism of CTSK and obesity role in breast cancer metastasis. Methods: Systematic review was performed using PubMed, EMBASE. The evidence of obesity and CTSK in breast cancer skeletal metastasis were analyzed, summarized and compared. Results: The present investigation argues for a specific association of CTSK with breast cancer skeletal metastasis by promoting adipocyte differentiation. The potential tumor-supporting roles of adipocytes are well documented, and in fact, suppressing adipocyte could be a new therapeutic option in the battle against lethal metastatic breast cancers. Conclusion: This review emphasizes CTSK through its multifaceted role in differentiating adipocytes, inflammation, and extracellular degradation, may be a critical factor in an obesity-cancer connection. Thus, integration of CTSK targeting strategies into established traditional therapies seems to hold substantial promise.

14 January 2025 in Reproductive Biology
Verified
Journal Article
Closed access
AAAditi S. Ambekar
Aditi S. Ambekar
NNNikita Naredi
Nikita Naredi
DMDipankar Malakar
Dipankar Malakar
YVY Vashum
Y Vashum
PMPratibha Misra
Pratibha Misra
MKMAHESH KULKARNI
MAHESH KULKARNI

12 March 2024 in Medical Journal Armed Forces India
Verified
Journal Article
Closed access
PMPratibha Misra
Pratibha Misra
PRPalaniswamy R
Palaniswamy R
DBDibyajyoti Boruah
Dibyajyoti Boruah
AGAnkita Gambhirrao
Ankita Gambhirrao
RGRuchira Godse
Ruchira Godse
YVY Vashum
Y Vashum

12 June 2024 in Medical Journal Armed Forces India
Verified
Journal Article
Closed access
NNNikita Naredi
Nikita Naredi
PMPratibha Misra
Pratibha Misra
PRPalaniswamy Ramaswamy
Palaniswamy Ramaswamy
RGRuchira Godse
Ruchira Godse
AGAnkita Gambhirrao
Ankita Gambhirrao
YVY Vashum
Y Vashum

27 April 2023 in Exploration of Medicine
Verified
Journal Article
Open access
PDF file
PMPratibha Misra
Pratibha Misra
RNRahul G Nath
Rahul G Nath
NNNikita Naredi
Nikita Naredi
Sibin M KSibin M K
Sibin M K
SRShyam Raj
Shyam Raj
YVY Vashum
Y Vashum
Aim: Polycystic ovarian syndrome (PCOS) is the most common endocrine condition, affecting 5–7% of reproductive-age women worldwide. It is associated with low-grade chronic inflammation, insulin resistance, and metabolic syndrome. Studies have shown ceruloplasmin (Cp) as an independent risk factor for metabolic syndrome and magnesium (Mg), which is required for proper glucose utilization. This study aimed to compare the serum Mg and Cp in PCOS and healthy women and correlate their levels with changes in biochemical, hormonal, and gynaecological aspects of PCOS. Methods: The study comprised 98 women diagnosed with PCOS using the Rotterdam criteria and 75 age-matched healthy control subjects. The level of serum Cp and Mg were determined using Somani Ambade colorimetric method and methylthymol blue method respectively. Results: Serum Cp was higher and Mg levels were lower significantly in PCOS patients in comparison with controls. Mg was inversely correlated with fasting blood glucose and directly correlated with follicle-stimulating hormone (FSH). Cp was inversely correlated with prolactin and thyroid-stimulating hormone. Multiple regression analysis revealed that Cp correlates with both the level of luteinizing hormone (LH) and LH/FSH ratio, whereas serum Mg did not have a significant correlation with any of the clinical variables. Logistic regression analysis revealed elevated Cp, antral follicle count (AFC), body mass index (BMI), weight, and irregular menses increase the risk of developing PCOS, whereas Mg was not a risk factor. However, high LH and LH/FSH ratios were risk factors for hypomagnesemia. In conclusion, serum Cp levels in PCOS may be evaluated as an additional risk factor in association with AFC, BMI, weight, and irregular menses. Conclusions: Mg deficiency and high Cp play an important etiological role in PCOS pathogenesis. Thus, research evaluating dietary interventions and supplementation is warranted.

1 May 2020 in Cancer and Oncology Research
Verified
Journal Article
Open access
PDF file
YVY Vashum
Y Vashum
KKKhashim Khashim
Khashim Khashim
FMFathima Bushra Sheriff M
Fathima Bushra Sheriff M
Cathepsin K (CTSK), a cysteine protease predominantly seen in osteoclasts, degrades protein present in the organic matrix of bone inducing bone resorption. Based on the accumulating evidences, CTSK has an established role in osteoclast mediated bone resorption, progression of cancer invasion, migration and extracellular matrix degradation through activating several pathways, which vary from other classes of cysteine proteinases such as Cathepsin B & L. Studies in the past have shown that CTSK is a key protease in breast cancer-induced bone metastases which are found highly expressed in human breast and prostate carcinomas. However, the involvement of CTSK in breast and prostate cancer development remains unclear. Bone is a key site of breast and prostate cancer metastasis and most patients with advanced disease encounter complications from incurable bone lesions. Therefore, CTSK can be viewed as an alternative target for treating patients with metastatic bone disease. This review discusses the molecular insights into CTSK and its specific targets in mediating breast cancer skeletal metastasis, so as to find the novelty of cathepsin K therapeutic target for the treatment of patients with osteolytic bone metastases.